A Phase 1B/2 Study of ACR-368 Alone and with Gemcitabine in People with Ovarian, Endometrial, or Urothelial Cancer

Full Title

Purpose

Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.

Participants in this study will receive either ACR-368 alone or ACR-368 plus low-dose gemcitabine, depending in the results of a test called OncoSignature (which measures the level of specific proteins in tumor cells). Both medications are given intravenously (by vein).

Contact

For more information about this study and to ask about eligibility, please contact Dr. Jonathan Rosenberg at 646-422-4461 or Dr. Chrisann Kyi at 646-888-4221.